Co-Diagnostics, Inc. short interest in 2025
In 2025, Co-Diagnostics, Inc.'s disclosed short interest ran from 0.82% of shares outstanding on 15 Jan 2025 to 1.06% on 15 Dec 2025, a change of +0.24 percentage points. The year's high was 2.81% on 14 Nov 2025 and its low 0.41% on 30 Apr 2025, averaging 1.07% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.88 days on 31 Jan 2025. Full history: Co-Diagnostics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 0.82% (15 Jan 2025)
- End of year
- 1.06% (15 Dec 2025)
- Change
- +0.24 pp
- High
- 2.81% (14 Nov 2025)
- Low
- 0.41% (30 Apr 2025)
- Average
- 1.07%
- Highest days to cover
- 2.88 (31 Jan 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2025 | 0.82% | 1.00 | |
| 31 Jan 2025 | 0.78% | 2.88 | |
| 14 Feb 2025 | 0.73% | 2.63 | |
| 28 Feb 2025 | 0.61% | 1.00 | |
| 14 Mar 2025 | 0.63% | 1.46 | |
| 31 Mar 2025 | 0.48% | 1.00 | 10-K filed, results (8-K) |
| 15 Apr 2025 | 0.43% | 1.00 | |
| 30 Apr 2025 | 0.41% | 1.42 | |
| 15 May 2025 | 0.49% | 1.00 | 10-Q filed, results (8-K) |
| 30 May 2025 | 1.17% | 1.00 | |
| 13 Jun 2025 | 0.84% | 1.00 | |
| 30 Jun 2025 | 0.84% | 1.00 | |
| 31 Jul 2025 | 1.78% | 1.00 | |
| 15 Aug 2025 | 1.33% | 1.00 | 10-Q filed, results (8-K) |
| 15 Sep 2025 | 2.06% | 1.94 | |
| 30 Sep 2025 | 1.14% | 1.00 | |
| 14 Nov 2025 | 2.81% | 1.00 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 1.87% | 1.00 | |
| 15 Dec 2025 | 1.06% | 1.00 |
See also: Co-Diagnostics, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.